115 results
DEFA14A
IMGN
Immunogen, Inc.
24 Jan 24
Additional proxy soliciting materials
4:57pm
proposals received by the Company, neither of the November 29 Proposals included any proposal regarding retention of the management of the Company following … the closing, and, as described in more detail in the section of this proxy statement captioned “Employment Agreements and Retention Arrangements
8-K
IMGN
Immunogen, Inc.
24 Jan 24
Other Events
4:55pm
retention of the management of the Company following the closing, and, as described in more detail in the section of this proxy statement captioned … “Employment Agreements and Retention Arrangements Through and Following the Merger”, none of the Company’s currently employed executive officers have
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
entitlement).
Employment Agreements and Retention Arrangements Through and Following the Merger
As of the date of this Schedule 14A, AbbVie has … or benefits, including retention, severance, or termination benefits, with respect to any of the Company’s or any of its
subsidiaries’ directors
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
to a pro rata bonus as part of a severance entitlement).
Employment Agreements and Retention Arrangements Through and Following the Merger … as in effect as of the date of the Merger Agreement, (A) increase the wages, salary or other compensation or benefits, including retention, severance
DEFA14A
IMGN
Immunogen, Inc.
21 Dec 23
Additional proxy soliciting materials
3:54pm
on the employee’s termination date.
Will retention payments be offered by ImmunoGen to any employees?
Given the acceleration of equity provided … to employees as part of this deal, retention payments are not being broadly offered. Retention payments may be offered to select employees; if offered
DEFA14A
EX-2.1
3unal6 fy6
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
EX-2.1
ipr8lb
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-1.1
fhessto0fdyc3ze beb
5 May 23
Entry into a Material Definitive Agreement
5:15pm
8-K
xis69s
28 Dec 22
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
4:40pm
8-K
EX-1.1
jzrp5q mku000p34
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm